RACGAP1 and breast carcinoma: The clinical correlation pathological study of RACGAP1, IRF7, and DMD showed that RACGAP1 was highly expressed in the high-risk group, indicating that RACGAP1 has a greater impact on patients with breast cancer infected with SARS-CoV-2 (Figure 4C; Table 2).